JP2014520874A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520874A5
JP2014520874A5 JP2014520661A JP2014520661A JP2014520874A5 JP 2014520874 A5 JP2014520874 A5 JP 2014520874A5 JP 2014520661 A JP2014520661 A JP 2014520661A JP 2014520661 A JP2014520661 A JP 2014520661A JP 2014520874 A5 JP2014520874 A5 JP 2014520874A5
Authority
JP
Japan
Prior art keywords
nanograms
compound
administered
need
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014520661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520874A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/064139 external-priority patent/WO2013014052A1/en
Publication of JP2014520874A publication Critical patent/JP2014520874A/ja
Publication of JP2014520874A5 publication Critical patent/JP2014520874A5/ja
Pending legal-status Critical Current

Links

JP2014520661A 2011-07-22 2012-07-19 組成物 Pending JP2014520874A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510624P 2011-07-22 2011-07-22
US61/510,624 2011-07-22
PCT/EP2012/064139 WO2013014052A1 (en) 2011-07-22 2012-07-19 Composition

Publications (2)

Publication Number Publication Date
JP2014520874A JP2014520874A (ja) 2014-08-25
JP2014520874A5 true JP2014520874A5 (enExample) 2015-08-06

Family

ID=46581948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520661A Pending JP2014520874A (ja) 2011-07-22 2012-07-19 組成物

Country Status (20)

Country Link
US (2) US10112946B2 (enExample)
EP (1) EP2734186B1 (enExample)
JP (1) JP2014520874A (enExample)
KR (1) KR101916928B1 (enExample)
CN (1) CN103841958A (enExample)
AU (2) AU2012289042A1 (enExample)
BR (1) BR112014001425A2 (enExample)
CA (1) CA2841361A1 (enExample)
CY (1) CY1120802T1 (enExample)
DK (1) DK2734186T3 (enExample)
ES (1) ES2693122T3 (enExample)
HR (1) HRP20181667T1 (enExample)
LT (1) LT2734186T (enExample)
PL (1) PL2734186T3 (enExample)
PT (1) PT2734186T (enExample)
RS (1) RS57995B1 (enExample)
RU (1) RU2631482C2 (enExample)
SI (1) SI2734186T1 (enExample)
SM (1) SMT201800642T1 (enExample)
WO (1) WO2013014052A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
JP2014520874A (ja) 2011-07-22 2014-08-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組成物
PE20150730A1 (es) 2012-08-24 2015-06-02 Glaxosmithkline Llc Compuestos de pirazolopirimidina
WO2014081645A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
AU2013348216B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1244668B1 (en) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
CN1814596A (zh) 2000-04-28 2006-08-09 阿卡蒂亚药品公司 毒蕈碱性激动剂
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
PL368129A1 (en) * 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
RU2217159C1 (ru) * 2002-03-18 2003-11-27 ООО "Содарм фарма" Раствор для ингаляций фармацевтической композиции глутовент и способ его терапевтического применения
DE60237425D1 (de) 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
CA2484921A1 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US6713241B2 (en) 2002-08-09 2004-03-30 Eastman Kodak Company Thermally developable emulsions and imaging materials containing binder mixture
CN100379750C (zh) 2002-08-21 2008-04-09 阿尔伯爱因斯坦医科叶希瓦大学 核苷磷酸化酶和核苷酶抑制剂
NZ539064A (en) 2002-09-27 2007-09-28 Dainippon Sumitomo Pharma Co Novel adenine compound and use thereof
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
WO2005025583A2 (en) 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
AU2004315876B2 (en) 2003-10-03 2011-05-26 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
EP1728792A4 (en) 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINE COMPOUND
TWI392678B (zh) 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co 9-取代-8-氧基腺嘌呤化合物
CN1960993A (zh) 2004-04-02 2007-05-09 Osi制药公司 6,6-双环取代的杂双环蛋白激酶抑制剂
CA2566158A1 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0611435A2 (pt) 2005-05-04 2010-09-08 Pfizer Ltd derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
NZ540160A (en) 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
JP2009502801A (ja) 2005-07-22 2009-01-29 サネシス ファーマシューティカルズ, インコーポレイテッド Auroraキナーゼインヒビターとして有用なピラゾロピリミジン
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
WO2007024944A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
CN101253173A (zh) 2005-09-02 2008-08-27 辉瑞有限公司 羟基取代的1h-咪唑并吡啶和方法
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090099216A1 (en) 2005-09-22 2009-04-16 Astrazeneca Aktiebolag A Corporation Of Sweden Novel adenine compound
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
JPWO2007034882A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
MX2008010611A (es) 2006-02-17 2008-11-12 Pfizer Ltd Derivados de 3-desazapurina como moduladores de receptores similares a toll.
CA2914168C (en) 2006-03-28 2018-05-08 Atir Holding S.A. Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
PT2125792E (pt) 2007-02-19 2011-03-01 Glaxosmithkline Llc Derivados de purina como imunomoduladores
WO2008114008A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
EP2139894B1 (en) 2007-03-19 2011-10-26 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
ES2541434T3 (es) 2007-06-29 2015-07-20 Gilead Sciences, Inc. Derivados de purina y su uso como moduladores del receptor de tipo Toll 7
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
TW200922569A (en) 2007-08-10 2009-06-01 Genelabs Tech Inc Certain nitrogen containing bicyclic chemical entities for treating viral infections
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
EP2326646B1 (en) 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
MX2011001662A (es) 2008-08-11 2011-03-24 Glaxosmithkline Llc Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas.
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
EP2320905B1 (en) * 2008-08-11 2017-06-28 Glaxosmithkline LLC Novel adenine derivatives
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
CN102548999A (zh) 2009-01-20 2012-07-04 山东轩竹医药科技有限公司 含有取代的含氮稠杂环的头孢菌素衍生物
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
CN102469790B (zh) 2009-08-07 2014-12-03 葛兰素史密丝克莱恩生物有限公司 脂质化氧代腺嘌呤衍生物
EA021048B1 (ru) 2010-02-10 2015-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
CA2826295C (en) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
JP2014520874A (ja) 2011-07-22 2014-08-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組成物
PE20150730A1 (es) 2012-08-24 2015-06-02 Glaxosmithkline Llc Compuestos de pirazolopirimidina
AU2013348216B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
WO2014081645A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
ES2655940T3 (es) 2014-02-20 2018-02-22 Glaxosmithkline Intellectual Property (No. 2) Limited Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano

Similar Documents

Publication Publication Date Title
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
JP2012193216A5 (enExample)
JP2010132695A5 (enExample)
JP2013014622A5 (enExample)
JP2013509429A5 (enExample)
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
JP2014520874A5 (enExample)
JP2016040316A5 (enExample)
JP2014521735A5 (enExample)
JP2010222367A5 (enExample)
JP2015038135A5 (enExample)
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
JP2018528966A5 (enExample)
JP2013541583A5 (enExample)
JP2011527301A5 (enExample)
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
FI3500241T3 (fi) Yhdistelmähoito copd:lle
AR100368A1 (es) Tratamiento de trastornos respiratorios
RU2013157398A (ru) Композиция
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
JP2011500731A5 (enExample)
JP2015533131A5 (enExample)
JP2016502992A5 (enExample)
JP2017530142A5 (enExample)